title: Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study.
abstract: The efficacy of trazodone and clorazepate to relieve anxiety and depressive symptoms in 21 HIV-positive subjects with adjustment disorders was determined in a 28-day single-centre, randomized, double-blind study. Subjects were evaluated using the Hospital Anxiety and Depression Scale, the Revised Symptom Checklist, the European Organization for Research and the Treatment of Cancer Quality of Life Questionnaire, and a binary criterion based on the Clinical Global Impression. The incidence of successful treatment was 80% for trazodone compared with 64% for clorazepate; the sample number was too small to establish a significant difference. Bayesian analysis revealed the probability of making a wrong decision in prescribing trazodone rather than clorazepate reduced from 35% to 18% in this small sample. Clinical evaluations using the different scales suggest some benefit from trazodone, although this was not significant. Safety of both treatments was similar. Trazodone is devoid of the risk of abuse and dependence, and may be a valuable alternative to benzodiazepines for the treatment of HIV-related adjustment disorders.
authors.affiliation: Department of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: De Wit
authors.forename: L
authors.initials: L
authors.lastname: Cremers
authors.forename: D
authors.initials: D
authors.lastname: Hirsch
authors.forename: C
authors.initials: C
authors.lastname: Zulian
authors.forename: N
authors.initials: N
authors.lastname: Clumeck
authors.forename: N
authors.initials: N
authors.lastname: Kormoss
mesh_terms: D000275:Adjustment Disorders / Q000188:drug therapy*; D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D003009:Clorazepate Dipotassium / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D015658:HIV Infections / Q000523:psychology*; D006801:Humans; D010865:Pilot Projects; D014196:Trazodone / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D003009:Clorazepate Dipotassium; D014196:Trazodone